Abstract 1008P
Background
TACE is the first choice for patients (pts) with intermediate-stage HCC. Numerous studies have demonstrated the limited survival benefit of TACE alone in pts with stage BCLC B, particularly in tumor beyond up-to-seven criteria. Single immunotherapy agent showed a certain effect for unresectable HCC pts, but still with unsatisfactory. This study was designed to explore the efficacy and safety of sintilimab plus cTACE for HCC with stage BCLC B (or stage CNLC IIa-IIb) beyond up-to-seven criteria.
Methods
This is a single-arm, phase II study(NCT04842565). Eligible HCC pts were treated cTACE and sintilimab (200mg, IV, Q3W). The first sintilimab dose was given after the first cTACE, and then every 3 weeks. The primary objectives were safety and progression-free survival (PFS). Secondary objectives included ORR assessed by both RECIST v1.1 and mRECIST v1.1, overall survival (OS), and disease control rate (DCR).
Results
From Oct 2020 to Feb 2023, 20 pts were enrolled with a median age of 62 years. All pts were BCLC stage B, and 45.0% (9/20) were CNLC IIa stage, 55.0% (11/20) were IIb stage. At median follow-up duration of 9.0 months, the ORR was 30.0%(95% CI: 14.6%-51.9%) per RECIST, and 60% (95%CI: 38.7%-78.1%) per mRECIST. The DCR was 95.0% (95% CI: 76.4%-99.1%) per both RECIST and mRECIST. Median PFS(by both RECIST and mRECIST) was 7.95 months (95% CI: 2.7-NA), and the median OS was not reached. Four pts converted to curative surgical resection. The optimal cut-off value of PLR(platelet-to-lymphocyte ratio) predicted tumor shrinkage was 100. Low PLR were associated with more tumor shrinkage. The most common TRAEs were hypothyroidism (37.5%), elevated aspartate aminotransferase (10.0%), rash(5.0%). Only one patient experienced grade 3 TRAE(myocarditis) and no treatment-related deaths were reported.
Conclusions
Combination of Sintilimab and cTACE showed promising antitumor activity and manageable toxicity in pts with HCC with BCLC stage B (CNLC stage IIa-IIb) beyond up-to-seven criteria. The PLR is promising predictor for tumor shrinkage in HCC. These strategy should be validated in a large randomized controlled trial.
Clinical trial identification
NCT04842565.
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan hospital affiliated to Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18